1



2,3

89%

2,4,5

  • 5
  • 5
  • 4
  • 5
  • 5
  • 2



6 7 8

 


1. Sonis S et al. J Clin Oncol 2001;19:2201–2205
2. Sonis S et al. Cancer 2004;100(Suppl 9):1995–2025
3. McGuire DB et al. Oncol Nurs Forum 1993;20:1493–1502
4. Anthony L et al. Support Care Cancer 2006;14:516–518
5. Avritscher EB et al. Semin Oncol Nurs 2004;20:3–10
6. Stokman MA et al. J Dent Res 2006;85:690–700
7. Redding SW. J Dent Educ 2005;69:919–929
8. Kostler WJ et al. CA Cancer J Clin 2001;51:290–315

This website contains information about Oral Mucositis and the use of Caphosol for the prevention and treatment of Oral Mucositis
Caphosol is a class I medical device, marked CE

©EUSA Pharma (Europe) Ltd. May 2009. All rights reserved. www.eusapharma.com
Registered in England 4555273 Registered Office The Magdalen Centre, Oxford Science Park, Oxford OX4 4GA Vat Registration No: 896 1192 88

www.caphosol.eu